acting as a GI checkpoint control (Hartwell, 1992; Lin et al., 1992) . One of the key genes regulated is known by several names (pici, WAFI, Cipl or Sdi) and produces p21 protein, which inhibits cyclin-dependent phosphorylation of important cell cycle regulators such as the product of the retinoblastoma gene (Levine, 1995) .
p53 is also involved in apoptosis, possibly in those cells which have sustained irreparable damage (Lane, 1992) , and mutation of this gene may partly explain the resiance of certain tumours to cytotoxic agents (Levin, 1995) . p53 appears to be crucial in damage control rather than normal development. Apoptotic response to radiation damage depends on normal p53 function -thymocytes from p53 knock-out mice are resistant to more than 20 Gy while control thymocytes show apoptosis at 1 Gy (Lane, 1993) . p53 is also involved in the therapeutic response to the topoisomerase 2 inhibitor, etoposide, by facilitating apoptosis (Clarke et al., 1993) . Point mutation in highly conserved regions of p53 causes loss of normal p53 protein function (Holstein et al., 1991) . p53 is a sequence-specific DNA-binding protein, and loss of the ability to interact with DNA is common in mutant p53 proteins (El-Deiry et al., 1992) . Murine models have shown that p53 can be bound by mdm-2 protein (Momand et al., 1992) . The human homologue of this gene has been shown to bind p53 in a way which switches off sequence-specific binding -high levels of mdm-2 may be tumorigenic by switching off p53, and many p53-associated proteins have been identified (Pietenpol and Vogelstein, 1993) . p53 protein may function by accumulating in response to DNA damage, thereby switching off replication to allow repair. Apoptosis is triggered if DNA repair fails. Inactivation of p53 by any of the methods outlined above would lead to accumulation of mutations and the selection of malignant clones (Lane, 1992) .
Studies on the murine p53 protein have shown that mutations affecting over 43% of the protein from residues 120-290 are capable of activating p53 for cooperation with ras in transforming cells (Levine, 1990) .
In murine models, mutant p53 protein has an increased half-life (from the normal 6-20 min to 4-8 h) and it is able to complex the hsp70 family of heat shock proteins. Such mutant proteins may also lose expression of the conformationally sensitive epitope recognised by the PAb 246 monoclonal antibody and instead express the pan-species conformationally resistant epitope recognised by the PAb 240 antibody (Lane and Benchimol, 1990) .
The p53 gene spans 20 kb of DNA on the short arm of human chromosome 17 and has one non-coding exon located several kilobases away from the ten coding exons (Levine, 1990) . There are five blocks of evolutionarily conserved amino acid sequence -the majority of mutations alter conserved amino acids in four of these regions (Lane and Benchimol, 1990) , and much research has therefore concentrated on the exons coding for these regions: 5, 6, 7 and 8. Recently, an immense amount of work has been done to characterise p53 mutations in relation to human neoplasia. In lung cancer p53 has been found to be frequently mutated (Takahashi et al., 1989) and is expressed abnormally (Iggo et al., 1990) . Mutation and abnormal expression has also been shown in breast cancer (Coles et al., 1990; Thompson et al., 1990) , gastric carcinoma (Seruca et al., 1992) , hepatocellular carcinoma (Bressac et al., 1990) and many other tumour types (Nigro et al., 1989) .
Abnormal p53 function has been implicated in haematological malignancies. Mice homozygous for a large deletion within the p53 gene all develop tumours by the age of 6 months, with a high incidence of T-cell lymphomas (Purdie et al., 1994) . Rearrangement of the gene associated with abnormal p53 expression has been found in chronic myeloid leukaemia (Ahuja et al., 1989; Mashal et al., 1990) . In Burkitt's lymphoma and its leukaemic counterpart mutations of p53 may be associated with an activated c-myc oncogene (Gaidano et al., 1991) Point mutation is associated with the detection of abnormal p53 expression. but abnormality stabilised protein can exist in the absence of p53 mutation (Wynford-Thomas, 1992) . It is also not clear whether immunocytochemistry or mutation analysis indicates the aggressiveness of a lymphoma. We have examined p53 with both mutation analysis (direct sequencing) and with immunocytochemistry using a polyclonal antibody (CM-1) in 38 lymphomas. CM-1 is raised against the wild-type p53 protein (Midgley et al., 1992) but is useful for detecting abnormally stabilised protein as the short half-life of normal p53 protein makes it hard to detect.
Materials and methods

Cases
Approval for the study was obtained from the local Joint Ethics Committee. Tumour samples of Hodgkin's disease and non-Hodgkin's lymphoma (NHL) were collected both fresh from surgical theatres and from samples received in the Department of Pathology, Aberdeen Royal Infirmary, from 1987 onwards and stored at -70°C. Most 'tumour' DNA was extracted from frozen specimens, although some was extracted from fresh samples from theatre before freezing. All the pathological specimens (H&E and CMI stained) were processed in the same way. The area of the specimen thought most likely to be representative of the tumour was chosen for these analyses. e.g. areas at the periphery of lymph nodes which may have contained normal tissue were avoided. The sections stained with CM1 polyclonal antibody were taken from tumour immediately adjacent to that from which DNA was extracted for SSCP analysis. This could not be guaranteed for every H&E-stained section as some of these were taken from the pathology archives. Cases were selected on the basis that either fresh or archival frozen material was available to provide sections for CM1 staining and also for DNA extraction. The tumours were classified according to the Kiel system (Lennert et al., 1983) and the Working Formulation (Anonymous, 1982) . The diagnoses of all tumours were reviewed by one pathologist (WDT) who also scored all the sections stained with CM1.
DNA extraction DNA was extracted from tumour tissue using standard cell lysis and phenol-chloroform purification techniques. The specimens were stored at -20'C if the DNA was not extracted immediately. Genomic DNA stock was kept physically separated from the area where the PCR reactions were prepared.
Single-strand conformation polv morphism (SSCP) analysis Point mutations were sought in exons 5-8 of p53 using 25 ng of template DNA in the amplification reactions and 10 pmol of the following primer pairs: exon 5 5'-TACTCCCCTGCCCTCAAC-3' 5'-GCCCCAGCTGCTCACCATCG-3' exon 6 5'-GGCCTCTGATTCCTCACTGATT-3' 5'-AGAGACCCCAGTTGCAA-3' exon 7 5'-CTTGCCACAGGTCTCCCCAA-3' 5'-AGGGGTCAGCGGCAAGCAGA-3' exon 8 5'-TGCTTCTCTIT--CCTATCCTGA-3' 5'-CGCTTCTTGTCCTGCTTGCT-3' The upstream primer of exon S was wholly exonic and the downstream primer included the last five bases of the exon. The other primers were wholly intronic. A 'master mix' was used to increase accuracy: 10 x polymerase chain reaction (PCR) Point mutations were detected by running the amplification product of a given exon on 8% non-denaturing acrylamide gels with 10% glycerol at 24'C for exon 5 or 5% nondenaturing '2% C' (Hayashi, 1991) acrylamide gels with 5% glycerol at 20'C for exons 6-8. A negative (no template) control was 'amplified' and run to detect PCR contamination and positive controls (samples with known mobility shifts) were run on each gel. Electrophoresis was done on the LKB 2010 Macrophor Sequencing System (LKB-Produkter. Bromma, Sweden) using a water-cooled thermostatic plate and the gels were then soaked in tap water for 15 min to prevent them adhering to the photographic film. After drying the gels were exposed at room temperature to Fuji RX film (Fuji Photo Film, Nomiya, Japan) to obtain a suitable autoradiograph (3-24 h). The PCR programme was 30 cycles of 94°C for 2 min, 60°C for 2 min and 72°C for 3 min. The antisense primer was biotinylated (exon 6, King's College, London; exons 5, 7 and 8, Genosys Biotechnologies, Cambridge, UK) at the 5' end to enable purification of the single-stranded template using streptavidin-conjugated magnetic beads (Dynabeads M-280 Streptavidin, Dy-al, Wirral, UK). The sequencing reactions were done with a 'Sequencing Kit (Pharmacia Biosystems, Central Milton Keynes, UK) using [a3SJdATP (Amersham) and the sense primer for each exon (exon 6 was sequenced using an additional internal sense primer 5'-TGGTTGCCCAGGGTCCCCAG-3'). The DNA fragments generated were separated by electrophoresis on 5% denaturing acrylamide wedge gels. All Infirmary. The sections were left to dry onto 0.1% poly-Llysine (Sigma, St Louis, MO, USA)-coated sldes overnight at room temperature. The sections were dewaxed in xykne and dehydrated in 100% alcohol. Endogenous peroxidase ativity was blocked by methanol-hydrogen peroxide. The section was then preincubated with 20% normal swine serum (Dako, A/S, Glostrup, Denark). CMI polyclonal antibody (a gift from Dr DP Lane, Department Biochemistry, University of Dundee, UK), used as a 1:1000 dilution, was incubated overnight. The avidin-biotin-peroxidase complex method was used (Hsu et al., 1981) . After development with diammobenzikine the sections were counterstained with haematoxylin, dehydrated and mounted.
Redt p53 mutations
All types of lymphoma were analysed for mutations in exons 5-8. Thirty-three cases of NHL (nine high-grade, 24 lowgrade) and five cases of Hodgkin's disease were studied. SSCP analysis was used to screen the 38 samples for single base changes, detected because of the different migation patterns of the wild-type and mutant radiolabelled DNA products when denatured and separated by polyacrylamide gel electphoresis under non-denaturing conditions. This screening method is fast, specific and sensitive (Gaidano et al., 1991) . To confirm and identify the abnormal nature of the DNA products of four samples showing band mobility shifts, direct sequencing was done and showed one silent and three missense mutations. Figure 1 shoes typical abnormal band mobility shifts in the SSCP analysis and Figure 2 shows the silent mutation in a case of Hodgin's disease. Table I shows the results of the immunocytochemistry by disease subtype. Table H details the four cases where a point mutation was characterised and shows the degree of CM1 antibody positivity for each case.
Three missnse mutations were characteised (Table II) in diffieent subtypes of B-cell NHL (one high-grade and two low-grade). The silent mutation (Figure 2) (Wynford-Thomas, 1992) . In addition, a non-mutational mechanism for p53 stabilisation has been proposed for those benign tssues which occasionally have positive staining for p53 (Vilhuendas et al., 1992) . Seven out of nine of those tumours staining positive showed no point mutation in exons 5-8 of p53, and one of the three lymphomas with missense mutations showed no positivity with CMI immunocytochimistry (sample 22). Lymphoma may be a disease which has an atypical spectrum of mutations outwith the exons usually involved in neoplasia, such as exons 4 and 9, which were not analysed for point mutation in this study. Kocialkowski et al. (1995) have demonstrated that this is the case in at least some cases of high-grade NHL. In addition, it is possible that the design of our exon 5 primers allowed some point mutations to remain undetected. Alternatively, positive immunocytochemistry apparently without point mutation could be attributed to insenstivity of the SSCP analysis or the direct sequencing of mutated exons when the presence of normal DNA masks the abnormality. Against this, however, is the finding of positive immunocytochemistry in cmnal cell hnes which have no p53 mutation -in addition, p53 may be stabilised by ras and thereby cause positive immunocytochemistry without gene mutation (Wynford-Thomas, 1992) . If such stabilisation of p53 protein occurs regularly in vivo without mutation of the gene then immunocytochemistry may provide more information about the neoplastic potential of a tumour than mutation analysis would.
Positive p53 immunocytochemistry may be associated with more aggesve neoplasia in lymphoma (Viluendas et al., 1992) and prostatic carcinoma (Visakorpi et al., 1992) . However, we would agree with other groups Kocialkowski et al., 1995) that, despite the association between p53 expression and mutation in certain tumours, immunocytochenistry cannot be used to determine which tumours have mutations of p53. Soini et al. (1992) found that the majority of their tumours which had abnormal p53 expression were of high-grade type. Although the use of archival material may have influenced the sekction of tumours studied, it is interesting that in this study 5/9 'high-grade' NHL tumours but only 3/24 'low-grade' NHL tumours stained positive for p53. 
